权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Late lead optimisation of orally available potassium channel inhibitors for the treatment of psoriasis

口服钾通道抑制剂治疗银屑病的后期先导优化

基本信息

批准号：
133656
负责人：
金额：
$ 56.82万
依托单位：
METRION BIOSCIENCES LTD
依托单位国家：
英国
项目类别：
Feasibility Studies
财政年份：
2018
资助国家：
英国
起止时间：
2018 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=133656
关键词：
Late lead optimisation orally available

项目摘要

"-- Metrion Bioscience Ltd (Metrion) is an ion channel specialist contract research organisation and has recently begun building its drug discovery and development capability. The company is based at Granta Park, Cambridge, with a core expertise in ion channel drug discovery and neuroscience. Metrion's R&D is focused on designing and discovering molecules for the treatment of debilitating Autoimmune disorders. The management team and advisors have extensive experience in this field and have previously raised significant equity funding and have a track record in delivering molecules to the clinic.-- Metrion is pioneering the discovery of oral medicines with the potential to change the underlying causes of psoriasis. The successful treatments for psoriasis predominantly provide symptomatic relief only, nevertheless this has created a $7bn market. Metrion's approach has the potential to radically modify/halt the progression of psoriasis impacting the patient and the healthcare system.-- Metrion through this grant will exploit its drug discovery expertise to identify small molecule inhibitors of potassium channels which has been linked to autoimmune disease and neurodegeneration. Further modification of these lead molecules subsequent to this project will allow the generation of orally active agents for the treatment of other autoimmune disease."

Metrion Bioscience Ltd（Metrion）是一家离子通道专家合同研究组织，最近开始建立其药物发现和开发能力。该公司总部位于剑桥的格兰塔公园，在离子通道药物发现和神经科学方面拥有核心专长。Metrion的研发专注于设计和发现用于治疗衰弱性自身免疫性疾病的分子。管理团队和顾问在这一领域拥有丰富的经验，之前已经筹集了大量的股权资金，并在向诊所提供分子方面有着良好的记录。Metrion是发现有可能改变银屑病根本原因的口服药物的先驱。牛皮癣的成功治疗主要只提供症状缓解，但这创造了70亿美元的市场。Metrion的方法有可能从根本上改变/停止影响患者和医疗保健系统的银屑病的进展。Metrion将利用其药物发现专业知识来识别与自身免疫性疾病和神经退行性疾病有关的钾通道小分子抑制剂。在该项目之后，这些先导分子的进一步修饰将允许产生用于治疗其他自身免疫性疾病的口服活性剂。"